Autologous Stem Cell Therapy: How Aging and Chronic Diseases Affect Stem and Progenitor Cells

BioResearch Open Access

Volumn 4, Issue 1, 2015, Pages 26-38

  Efimenko, Anastasia Yu ^a   Kochegura, Tatiana N ^a   Akopyan, Zhanna A ^a   Parfyonova, Yelena V ^a,b  

^a MOSCOW STATE UNIVERSITY   (Russian Federation)

^b INSTITUTE OF EXPERIMENTAL CARDIOLOGY   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

AGING; AUTOLOGOUS STEM CELL TRANSPLANTATION; CHRONIC DISEASE; CORONARY ARTERY DISEASE; HUMAN; HYPERGLYCEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PARACRINE SIGNALING; PRIORITY JOURNAL; REGENERATIVE MEDICINE; REVIEW; RISK FACTOR;

EID: 85014731969     PISSN: None     EISSN: 21647860     Source Type: Journal    
DOI: 10.1089/biores.2014.0042     Document Type: Review

References (117)

1. Belenkov YuN, Mareev VYu, Ageev FT. Chronic heart failure. Selected lectures on cardiology [In Russian]. GEOTAR-Media: Moscow, 2006.
2. Yancy C, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;128:e240-e327.
3. World Health Organization. WHO global InfoBase, 2008. Available at: http://www.who.int/infobase (accessed October 21, 2013).
4. American Diabetes Association; National Heart, Lung and Blood Institute; Juvenile Diabetes Foundation International; National Institute of Diabetes and Digestive and Kidney Disease; American Heart Association. Diabetes mellitus: a major risk factor for cardiovascular disease. Circulation. 1999;100:1132-1133.
5. Kotseva K, Wood D, De Backer G, et al. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil. 2009;16:121-137.
6. Ageev FT. Role of endothelial dysfunction in the development and progression of cardiovascular disease [In Russian]. J Heart Failure. 2003;4:22-24.
7. Balabolkin MI, Klebanova EM, Kreminskaya VM. Treatment of diabetes mellitus and its complications. Medicine: Moscow, Russia; pp. 304-414; 2005.
8. Spinetti G, Kraenkel N, Emanueli C, et al. Diabetes and vessel wall remodelling: from mechanistic insights to regenerative therapies. Cardiovasc Res. 2008;78:265-273.
9. Valina C, Pinkernell K, Song YH, et al. Intracoronary administration of autologous adipose tissue-derived stem cells improves left ventricular function, perfusion, and remodelling after acute myocardial infarction. Eur Heart J. 2007;28:2667-2677.
10. Madonna R, De Caterina R. Adipose tissue: a new source for cardiovascular repair. J Cardiovasc Med (Hagerstown). 2010;11:71-80.
11. Williams AR, Hare JM. Mesenchymal stem cells: biology, pathophysiology, translational findings, and therapeutic implications for cardiac disease. Circ Res. 2011;109:923-940.
12. Hsiao LC, Carr C, Chang KC, et al. Review article: stem cell-based therapy for ischemic heart disease. Cell Transplant. 2013;22:663-675.
13. Mathiasen AB, Haack-Sørensen M, Jørgensen E, et al. Autotransplantation of mesenchymal stromal cells from bone-marrow to heart in patients with severe stable coronary artery disease and refractory angina -final 3-year follow-up. Int J Cardiol. 2013;170:246-251.
14. Bura A, Planat-Benard V, Bourin P, et al. Phase I trial: the use of autologous cultured adipose-derived stroma/stem cells to treat patients with non-revascularizable critical limb ischemia. Cytotherapy. 2014;16: 245-257.
15. Zuk PA, Zhu M, Ashjian P, et al. Human adipose tissue is a source of multipotent stem cells. Mol Biol Cell. 2002;13:4279-4295.
16. Hill J, Zalos G, Halcox JP. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med. 2003;348:593-600.
17. Siddique A, Shantsila E, Lip GY, et al. Endothelial progenitor cells: what use for the cardiologist? J Angiogenes Res. 2010;2:6.
18. Nombela-Arrieta C, Ritz J, Silberstein LE. The elusive nature and function of mesenchymal stem cells. Nat Rev Mol Cell Biol. 2011;12: 126-131.
19. Germani A, Di Campli C, Pompilio G. Regenerative therapy in peripheral artery disease. Cardiovasc Ther. 2009;27:289-304.
20. Jezierska-Woźniak K, Mystkowska D, Tutas A, et al. Stem cells as therapy for cardiac disease -a review. Folia Histochem Cytobiol. 2011;49:13-25.
21. Mizuno H, Tobita M, Uysal C. Concise review: adipose-derived stem cells as a novel tool for future regenerative medicine. Stem Cells. 2012;30:804-810.
22. Gimble JM, Bunnell BA, Frazier T, et al. Adipose derived stromal/stem cells: a primer. Organogenesis. 2013;9:3-10.
23. Rando TA. Stem cells, ageing and the quest for immortality. Nature. 2006;441:1080-1086.
24. Oh J, Lee YD, Wager AJ. Stem cell aging: mechanisms, regulators and therapeutic opportunities. Nat Med. 2014;20:870-880.
25. Flores I, Blasco MA. The role of telomeres and telomerase in stem cell aging. FEBS Lett. 2010;584:3826-3830.
26. Dasgupta J, Kar S, Liu R, et al. Reactive oxygen species control senescence-associated matrix metalloproteinase-1 through c-Jun-N-terminal kinase. J Cell Physiol. 2010;225:52-62.
27. Wang C, Jurk D, Maddick M, et al. DNA damage response and cellular senescence in tissues of aging mice. Aging Cell. 2009;8: 311-323.
28. Sethe S, Scutt A, Stolzing A. Aging of mesenchymal stem cells. Ageing Res Rev. 2006;5:91-116.
29. Campisi J, Robert L. Cell senescence: role in aging and age-related diseases. Interdiscip Top Gerontol. 2014;39:45-61.
30. Stolzing A, Jones E, McGonagle D, et al. Age-related changes in human bone marrow-derived mesenchymal stem cells: consequences for cell therapies. Mech Ageing Dev. 2008;129:163-173.
31. Sun Y, Li W, Lu Z, et al. Rescuing replication and osteogenesis of aged mesenchymal stem cells by exposure to a young extracellular matrix. FASEB J. 2011;25:1474-1485.
32. Siegel G, Kluba T, Hermanutz-Klein U, et al. Phenotype, donor age and gender affect function of human bone marrow-derived mesenchymal stromal cells. BMC Med. 2013;11:146.
33. Fan M, Chen W, Liu W, et al. The effect of age on the efficacy of human mesenchymal stem cell transplantation after a myocardial infarction. Rejuvenation Res. 2010;13:429-438.
34. de Girolamo L, Lopa S, Arrigoni E, et al. Human adipose-derived stem cells isolated from young and elderly women: their differentiation potential and scaffold interaction during in vitro osteoblastic differentiation. Cytotherapy. 2009;11:793-803.
35. Harris LJ, Zhang P, Abdollahi H, et al. Availability of adipose-derived stem cells in patients undergoing vascular surgical procedures. J Surg Res. 2010;163:e105-e112.
36. Zhu M, Kohan E, Bradley J, et al. The effect of age on osteogenic, adipogenic and proliferative potential of female adipose-derived stem cells. J Tissue Eng Regen Med. 2009;3:290-301.
37. Huang SC, Wu TC, Yu HC, et al. Mechanical strain modulates age-related changes in the proliferation and differentiation of mouse adiposederived stromal cells. BMC Cell Biol. 2010;11:18.
38. Alt EU, Senst C, Murthy SN, et al. Aging alters tissue resident mesenchymal stem cell properties. Stem Cell Res. 2012;8:215-225.
39. van Harmelen V, Skurk T, Rohrig K, et al. Effect of BMI and age on adipose tissue cellularity and differentiation capacity in women. Int J Obes Relat Metab Disord. 2003;27:889-895.
40. Schipper BM, Marra KG, Zhang W, et al. Regional anatomic and age effects on cell function of human adipose-derived stem cells. Ann Plast Surg. 2008;60:538-544.
41. Khan WS, Adesida AB, Tew SR, et al. The epitope characterisation and the osteogenic differentiation potential of human fat pad-derived stem cells is maintained with ageing in later life. Injury. 2009;40: 150-157.
42. El-Ftesi S, Chang EI, Longaker MT, et al. Aging and diabetes impair the neovascular potential of adipose-derived stromal cells. Plast Reconstr Surg. 2009;123:475-485.
43. Sahin E, Depinho RA. Linking functional decline of telomeres, mitochondria and stem cells during ageing. Nature. 2010;464:520-528.
44. Lin CS, Xin ZC, Deng CH, et al. Defining adipose tissue-derived stem cells in tissue and in culture. Histol Histopathol. 2010;25:807-815.
45. Efimenko A, Starostina E, Kalinina N, et al. Angiogenic properties of aged adipose derived mesenchymal stem cells after hypoxic conditioning. J Translat Med. 2011;9:10-22.
46. Efimenko A, Dzhoyashvili NA, Kalinina NI, et al. Adipose-derived stromal cells (ADSC) from aged patients with coronary artery disease keep MSC properties but exhibit age markers and have an impaired angiogenic potential. Stem Cells Translat Med. 2014;3:32-41.
47. Melzer D, Frayling TM, Murray A, et al. A common variant of the p16(INK4a) genetic region is associated with physical function in older people. Mech Ageing Dev. 2007;128:370-377.
48. De Barros S, Dehez S, Arnaud E, et al. Aging-related decrease of human ASC angiogenic potential is reversed by hypoxia preconditioning through ROS production. Mol Ther. 2013;21:399-408.
49. Bratic A, Larsson NGG. The role of mitochondria in aging. J Clin Invest. 2013;123:951-957.
50. Pandey AC, Semon JA, Kaushal D, et al. MicroRNA profiling reveals agedependent differential expression of nuclear factor jB and mitogenactivated protein kinase in adipose and bone marrow-derived human mesenchymal stem cells. Stem Cell Res Ther. 2011;2:49.
51. Efimenko A, Starostina EE, Kalinina NI, et al. Age effects on angiogenic properties of adipose tissue mesenchymal stem cells. Cell Transpl Tissue Eng. 2011;6:48-57.
52. Wang M, Monticone RE, Lakatta EG. Arterial aging: a journey into subclinical arterial disease. Curr Opin Nephrol Hypertens. 2010;19:201-207.
53. Traktuev DO, Tsokolaeva ZI, Shevelev AA, et al. Urokinase gene transfer augments angiogenesis in ischemic skeletal and myocardial muscle. Mol Ther. 2007;15:1939-1946.
54. Hoenig MR, Bianchi C, Rosenzweig A, et al. Decreased vascular repair and neovascularization with ageing: mechanisms and clinical relevance with an emphasis on hypoxia-inducible factor-1. Curr Mol Med. 2008;8:754-767.
55. Vasa M, Fichtlscherer S, Aicher A, et al. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res. 2001;89:E1-E7.
56. Choi JH, Hur J, Yoon CH. Augmentation of therapeutic angiogenesis using genetically modified human endothelial progenitor cells with altered glycogen synthase kinase-3beta activity. J Biol Chem 2004;279:4943-4948.
57. Madonna R, Renna FV, Cellini C, et al. Age-dependent impairment of number and angiogenic potential of adipose tissue-derived progenitor cells. Eur J Clin Invest. 2011;41:126-133.
58. Takahashi M, Izawa A, Ishigatsubo Y, et al. Therapeutic neovascularization by implantation of autologous mononuclear cells for patients with connective tissue diseases. Curr Pharm Des. 2009;15:2778-2783.
59. Eizawa T, Ikeda U, Murakami Y, et al. Decrease in circulating endothelial progenitor cells in patients with stable coronary artery disease. Heart. 2004;90:685-686.
60. Kochegura TN, Akopyan ZhA, Sharonov GV, et al. The influence of concomitant type 2 diabetes mellitus on the number of circulating progenitor cells in patients with ischemic cardiomyopathy. Diabetes Mellitus. 2011;3:36-43.
61. Bozdag-Turan I, Turan RG, Paranskaya L, et al. Correlation between the functional impairment of bone marrow-derived circulating progenitor cells and the extend of coronary artery disease. J Transl Med. 2012;10:143.
62. Loomans CJ, de Koning EJ, Staal FJ, et al. Endothelial progenitor cell dysfunction: a novel concept in the pathogenesis of vascular complications of type 1 diabetes. Diabetes. 2004;53:195-199.
63. Chen JZ, Zhang FR, Tao QM, et al. Number and activity of endothelial progenitor cells from peripheral blood in patients with hypercholesterolaemia. Clin Sci (Lond). 2004;107:273-280.
64. MacEneaney OJ, Kushner EJ, Westby CM, et al. Endothelial progenitor cell function, apoptosis, and telomere length in overweight/obese humans. Obesity. 2010;18:1677-1682.
65. Drela E, Stankowska K, Kulwas A, et al. Endothelial progenitor cells in diabetic foot syndrome. Adv Clin Exp Med. 2012;21:249-254.
66. van Ark J, Moser J, Lexis CP, et al. Type 2 diabetes mellitus is associated with an imbalance in circulating endothelial and smooth muscle progenitor cell numbers. Diabetologia. 2012;55:2501-2512.
67. Gu JH, Lee JS, Kim DW, et al. Neovascular potential of adipose-derived stromal cells (ASCs) from diabetic patients. Wound Repair Regen. 2012;20:243-252.
68. Oñ ate B, Vilahur G, Ferrer-Lorente R, et al. The subcutaneous adipose tissue reservoir of functionally active stem cells is reduced in obese patients. FASEB J. 2012;26:4327-4336.
69. Vecellio M, Spallotta F, Nanni S, et al. The histone acetylase activator pentadecylidenemalonate 1b rescues proliferation and differentiation in human cardiac mesenchymal cells of type 2 diabetic patients. Diabetes. 2014;63:2132-2147.
70. Dzhoyashvili NA, Efimenko A, Akchurin RS, et al. Angiogenic properties of multipotent mesenchymal stromal cells of adipose tissue of patients with coronary heart disease. Russian J Cardiol. 2013;5:27-34.
71. Babaei S, Teichert-Kuliszewska K, Zhang Q, et al. Angiogenic actions of angiopoietin-1 require endothelium-derived nitric oxide. Am J Pathol. 2003;162:1927-1936.
72. Kolluru GK, Bir SC, Kevil CG. Endothelial dysfunction and diabetes: effects on angiogenesis, vascular remodeling, and wound healing. Int J Vasc Med. 2012;2012:918267.
73. Dua MM, Miyama N, Azuma J, et al. Hyperglycemia modulates plasminogen activator inhibitor-1 expression and aortic diameter in experimental aortic aneurysm disease. Surgery. 2010;148:429-435.
74. Gabriely I, Yang XM, Cases JA, et al. Hyperglycemia induces PAI-1 gene expression in adipose tissue by activation of the hexosamine biosynthetic pathway. Atherosclerosis. 2002;160:115-122.
75. Weiss TW, Seljeflot I, Hjerkinn EM, et al. Adipose tissue pro-inflammatory gene expression is associated with cardiovascular disease. Int J Clin Pract. 2011;65:939-944.
76. Acosta L, Hmadcha A, Escacena N, et al. Adipose mesenchymal stromal cells isolated from type 2 diabetic patients display reduced fibrinolytic activity. Diabetes. 2013;62:4266-4269.
77. Tashiro Y, Nishida C, Sato-Kusubata K, et al. Inhibition of PAI-1 induces neutrophil-driven neoangiogenesis and promotes tissue regeneration via production of angiocrine factors in mice. Blood. 2012;119:6382-6393.
78. Stefansson S, McMahon GA, Petitclerc E, et al. Plasminogen activator inhibitor-1 controls bone marrow-derived cells therapeutic effect through MMP9 signaling: role in physiological and pathological wound healing. Curr Pharm Des. 2003;9:1545-1564.
79. Simonavicius N, Ashenden M, Weverwijk A, et al. Pericytes promote selective vessel regression to regulate vascular patterning. Blood. 2012;120:1516-1527.
80. Kalinina NI, Akopyan ZhA, Pakhomova EA, et al. Effects of hyperglycemia on functional state of human umbilical vein endothelial cells in vitro. Dokl Biol Sci. 2009;426:210-212.
81. Akopyan ZhA, Sharonov GV, Kochegura TN, et al. The influence of high glucose concentration on the ability of mesenchymal stromal cells to stimulate blood vessel growth. Diabetes Mellitus. 2011;2:32-36.
82. Urbich C, Dimmeler S. Endothelial progenitor cells: characterization and role in vascular biology. Circ Res. 2004;95:343-353.
83. Chen YH, Lin SJ, Lin FY. High glucose impairs early and late endothelial progenitor cells by modifying nitric oxide-related but not oxidative stress-mediated mechanisms. Diabetes. 2007;56:1559-1568.
84. Churdchomjan W, Kheolamai P, Manochantr S, et al. Comparison of endothelial progenitor cell function in type 2 diabetes with good and poor glycemic control. BMC Endocr Disord. 2010;10:5.
85. Asahara T, Murohara T, Sullivan A. Isolation of putative progenitor endothelial cells for angiogenesis. Science. 1997;275:964-967.
86. Yoder MC, Mead LE, Prater D, et al. Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals. Blood. 2007;109:1801-1809.
87. Fisher JC. Endothelial progenitor cells. In: Cellular Diagnostics: Basics, Methods and Clinical Applications of Flow Cytometry. Sack U, Tárnok A, Rothe G (eds). Karger: Basel; pp. 305-316; 2009.
88. Pujol BF, Lucibello FC, Gehling UM. Endothelial-like cells derived from human CD14 positive monocytes. Differentiation. 2000;65:287-300.
89. Rookmaaker MB, Vergeer M, van Zonneveld AJ, et al. Endothelial progenitor cells: mainly derived from the monocyte/macrophage-containing CD34 mononuclear cell population and only in part from the hematopoietic stem cell-containing CD34 + mononuclear cell population. Circulation. 2003;108:e150.
90. Springer ML. A balancing act: therapeutic approaches for the modulation of angiogenesis. Curr Opin Investig Drugs. 2006;7:243-250.
91. Herrmann JL, Abarbanell AM, Weil BR, et al. Optimizing stem cell function for the treatment of ischemic heart disease. J Surg Res. 2011;166:138-145.
92. Das R, Jahr H, van Osch GJ, et al. The role of hypoxia in bone marrowderived mesenchymal stem cells: considerations for regenerative medicine approaches. Tissue Eng Part B Rev. 2010;16:159-168.
93. Buravkova LB, Grinakovskaya OS, Andreeva ER, et al. Characteristics of human lipoaspirate-isolated mesenchymal stromal cells cultivated under a lower oxygen tension. Cytology. 2009;51:5-10.
94. Efimenko AYu, Starostina EE, Rubina KA, et al. Viability and angiogenic activity of mesenchymal stromal cells from adipose tissue and bone marrow in hypoxia and inflammation in vitro [In Russian]. Tsitologiia. 2010;52:144-154.
95. Kalinina NI, Efimenko AYu, Starostina EE, et al. Hypoxia as the main activator of angiogenesis and fatty tissue growth. Russian J Physiol. 2009;95:283-289.
96. Rehman J, Traktuev D, Li J, et al. Secretion of angiogenic and antiapoptotic factors by human adipose stromal cells. Circulation. 2004;109:1292-1298.
97. Thangarajah H, Vial IN, Chang E, et al. IFATS collection: adipose stromal cells adopt a proangiogenic phenotype under the influence of hypoxia. Stem Cells. 2009;27:266-274.
98. Hu X, Yu SP, Fraser JL, et al. Transplantation of hypoxia-preconditioned mesenchymal stem cells improves infarcted heart function via enhanced survival of implanted cells and angiogenesis. J Thorac Cardiovasc Surg. 2008;135:799-808.
99. Rubina KA, Kalinina NI, Efimenko AYu, et al. Adipose stromal cells stimulate angiogenesis via promoting progenitor cell differentiation, secretion of angiogenic factors, and enhancing vessel maturation. Tissue Eng Part A. 2009;15:2039-2050.
100. Rubin JP, DeFail A, Rajendran N, et al. Encapsulation of adipogenic factors to promote differentiation of adipose-derived stem cells. J Drug Target. 2009;17:207-215.
101. Suga H, Matsumoto D, Eto H, et al. Functional implications of CD34 expression in human adipose-derived stem/progenitor cells. Stem Cells Dev. 2009;18:1201-1210.
102. Hebert TL, Wu X, Yu G, et al. Culture effects of epidermal growth factor (EGF) and basic fibroblast growth factor (bFGF) on cryopreserved human adipose-derived stromal/stem cell proliferation and adipogenesis. J Tissue Eng Regen Med. 2009;3:553-561.
103. Dimmeler S, Aicher A, Vasa M, et al. HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. J Clin Invest. 2001;108:391-397.
104. Seeger FH, Haendeler J, Walter DH, et al. p38 mitogen-activated protein kinase downregulates endothelial progenitor cells. Circulation. 2005;111:1184-1191.
105. Mias C, Trouche E, Seguelas MH, et al. Ex vivo pretreatment with melatonin improves survival, proangiogenic/mitogenic activity, and efficiency of mesenchymal stem cells injected into ischemic kidney. Stem Cells. 2008;26:1749-1757.
106. Lutolf MP, Gilbert PM, Blau HM. Designing materials to direct stem-cell fate. Nature. 2009;462:433-441.
107. Shevchenko EK, Makarevich PI, Tsokolaeva ZI, et al. Effective transduction of human adipose stromal cells by a recombinant adeno-associated virus. Cell Transpl Tissue Eng. 2010;5:60-64.
108. Shevchenko EK, Makarevich PI, Tsokolaeva ZI, et al. Transplantation of modified human adipose derived stromal cells expressing VEGF165 results in more efficient angiogenic response in ischemic skeletal muscle. J Transl Med. 2013;11:138.
109. Yao J, Jiang SL, Liu W, et al. Tissue inhibitor of matrix metalloproteinase-3 or vascular endothelial growth factor transfection of aged human mesenchymal stem cells enhances cell therapy after myocardial infarction. Rejuvenation Res. 2012;15:495-506.
110. Tang H, Xiang Y, Jiang X, et al. Dual expression of hTERT and VEGF prolongs life span and enhances angiogenic ability of aged BMSCs. Biochem Biophys Res Commun. 2013;440:502-508.
111. Fadini GP, Agostini C, Avogaro A. Autologous stem cell therapy for peripheral arterial disease meta-analysis and systematic review of the literature. Atherosclerosis. 2010;209:10-17.
112. Clifford DM, Fisher SA, Brunskill SJ, et al. Stem cell treatment for acute myocardial infarction. Cochrane Database Syst Rev. 2012;2:CD006536.
113. Lalu MM, McIntyre L, Pugliese C, et al. Canadian Critical Care Trials Group Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials. PLoS One. 2012;7:e47559.
114. Fisher SA, Dorée C, Brunskill SJ, et al. Bone marrow stem cell treatment for ischemic heart disease in patients with no option of revascularization: a systematic review and meta-analysis. PLoS One. 2013;8:e64669.
115. Delewi R, Andriessen A, Tijssen JG, et al. Impact of intracoronary cell therapy on left ventricular function in the setting of acute myocardial infarction: a meta-analysis of randomised controlled clinical trials. Heart. 2013;99:225-232.
116. Benoit E, O'Donnell TF, Patel AN. Safety and efficacy of autologous cell therapy in critical limb ischemia: a systematic review. Cell Transplant. 2013;22:545-562.
117. Fisher SA, Brunskill SJ, Doree C, et al. Stem cell therapy for chronic ischemic heart disease and congestive heart failure. Cochrane Database Syst Rev. 2014;4:CD007888.